CN107759607B - Triazole with anti-tumor activity and phenodiazine Zhuo compound and preparation method thereof - Google Patents

Triazole with anti-tumor activity and phenodiazine Zhuo compound and preparation method thereof Download PDF

Info

Publication number
CN107759607B
CN107759607B CN201711220507.8A CN201711220507A CN107759607B CN 107759607 B CN107759607 B CN 107759607B CN 201711220507 A CN201711220507 A CN 201711220507A CN 107759607 B CN107759607 B CN 107759607B
Authority
CN
China
Prior art keywords
reaction
phenyl
added
pyriconyl
raw material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711220507.8A
Other languages
Chinese (zh)
Other versions
CN107759607A (en
Inventor
毛龙飞
胡娅伦
刘国锋
侯茜茜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Wanxiang Pharmaceutical Co., Ltd.
Original Assignee
SHANGHAI WANXIANG PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI WANXIANG PHARMACEUTICAL Co Ltd filed Critical SHANGHAI WANXIANG PHARMACEUTICAL Co Ltd
Priority to CN201711220507.8A priority Critical patent/CN107759607B/en
Publication of CN107759607A publication Critical patent/CN107759607A/en
Application granted granted Critical
Publication of CN107759607B publication Critical patent/CN107759607B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of triazole with anti-tumor activity and phenodiazine Zhuo compounds and preparation method thereof, belong to medical synthesis technical field.Technical key point of the present invention are as follows:

Description

Triazole with anti-tumor activity and phenodiazine Zhuo compound and preparation method thereof
Technical field
The invention belongs to medical synthesis technical fields, and in particular to a kind of triazole with anti-tumor activity and phenodiazine is tall and erect Compound and preparation method thereof.
Background technique
The important heterocyclic compound with pharmacological activity of Benzodiazepines compound Shi ー kind, have calmness, hypnosis, The effects of anti-epileptic, central of flaccid muscles, when it acts on human body, has the characteristics that rapid-action, safe.Central nervous system It is middle to there is the binding site that there is high-affinity, stereospecificity and saturability to Benzodiazepine.And most of benzene phenodiazines Tall and erect class drug is related to the affinity of binding site and their pharmacological action, and central action has with Benzodiazepine binding site It closes.Further investigation also found distribution situation and the CNS inhibition neurotransmitter GABA of Benzodiazepine binding site (GABA) distribution of GABAA receptor is almost the same.Electro physiology is it is demonstrated experimentally that Benzodiazepines can enhance GABA energy neurotransmission Function and cynapse depression effect;The effect that GABA is combined with GABAA receptor can also be enhanced.
Triazole has certain physiological activity, in terms of as antiseptic medicine research, due to its efficient, hypotoxicity, secondary work With small advantage, increasingly by the concern of scientist.In Benzodiazepine parent nucleus 1,2 upper introducing imidazoles or triazole ring etc. The compound of heterocycle, is clinically widely applied, and mainly has alprazolam, estazolam, midazolam etc..At present for 1, the 2 introducing heterocycle modifications of Benzodiazepine parent nucleus and the derivative to the modification of 4,5 introducing heterocycles, document have more report Road.This research obtains novel diazo in 2,3 introducing triazole rings of Benzodiazepine parent nucleus by design synthetic route And benzodiazepine compound.
Summary of the invention
The technical problem to be solved by the present invention is to provide a kind of novel triazoles with anti-tumor activity of molecular structure And phenodiazine Zhuo compound and preparation method thereof.
A kind of triazole with anti-tumor activity and phenodiazine Zhuo compound, the compound are shown below:
A kind of preparation method of triazole with anti-tumor activity and phenodiazine Zhuo compound, it is characterised in that specific steps Are as follows:
A, acylation reaction generation N- phenyl trimethicone acetamide occurs in pyridine or methylene chloride for aniline and pivaloyl chloride;
B, N- phenyl trimethicone acetamide activates under that action of n-butyl lithium occurs addition with 4- pyridine carboxaldehyde after ortho-hydrogens Reaction obtains N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine;
C, N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine is aoxidized by manganese dioxide or chromium trioxide, Secondary carbon and the hydroxyl connected generate carbonyl after sloughing a molecule hydrogen in its structure, obtain N- (2- (4- piperidone base) phenyl) Pivaloyl amine;
D, N- (2- (4- piperidone base) phenyl) pivaloyl amine sloughs tertiary bytyry in acid condition and obtains 2- (4- Piperidone base) aniline;2- (4- piperidone base) aniline occurs substitution reaction with Boc glycyl chlorine under DCC effect and generates N- (2- (4- piperidone base) phenyl) Boc amino acetamide;
E, N- (2- (4- piperidone base) phenyl) Boc amino acetamide reacts in Isosorbide-5-Nitrae-dioxane or THF with HCl, N- (2- (4- piperidone base) phenyl) glycyl amine hydrochlorate is obtained at salt while sloughing Boc group;
F, N- (2- (4- piperidone base) phenyl) glycyl amine hydrochlorate occurs ketoamine and is condensed under sodium methoxide effect To tall and erect -2 (3H) -one of 5- (4- pyridyl group) -1H- benzo [e] [1,4] phenodiazine;
G, tall and erect -2 (3H) -one of 5- (4- pyridyl group) -1H- benzo [e] [1,4] phenodiazine and TMSN3Or NaN3Click is occurring Reaction obtains
It further limits, the detailed process of step A are as follows: in reaction flask, aniline is added in pyridine, in room temperature condition Under, pivaloyl chloride is slowly added dropwise, continues to react at room temperature after dripping, TLC monitors raw material fully reacting, to reaction solution It is middle to be added a certain amount of HCl solution, strong stirring for a period of time after washed reaction liquid, be finally concentrated to get under vacuum conditions N- phenyl trimethicone acetamide;Or in reaction flask, aniline and potassium carbonate are added in methylene chloride and stirred, in room temperature condition Under, pivaloyl chloride is slowly added dropwise, continues to react at room temperature after dripping, TLC monitors raw material fully reacting, to reaction solution It is middle to be added a certain amount of HCl solution, strong stirring for a period of time after washed reaction liquid, be finally concentrated to get N- under vacuum conditions Phenyl trimethicone acetamide.
Further limit, the detailed process of step B are as follows: in reaction flask, N- phenyl trimethicone acetamide be added to through In the THF of Non-aqueous processing, nitrogen protection reaction system is placed under the conditions of 0 DEG C, and n-butyllithium solution is slowly added dropwise, and keeps temperature At 5 DEG C hereinafter, stirring 2h after dripping, the THF solution dissolved with 4- pyridine carboxaldehyde is slowly dropped in reaction solution, makes reaction temperature Degree is no more than 5 DEG C, drips rear reaction solution in peony;It is complete that the reaction was continued 3h, TLC monitor raw material unreacted, and reaction is made to exist A certain amount of ice water quenching reaction is added after the reaction was continued 8h under the conditions of temperature is -20 DEG C~60 DEG C, then is extracted with ethyl acetate Reaction solution obtains the crude product of N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine after organic phase is evaporated off, then passes through Column chromatography for separation obtains sterling.
It further limits, the detailed process of step C are as follows: in reaction flask, N- (2- (hydroxyl (4- pyridyl group) methyl) benzene Base) pivaloyl amine and MnO2It is added in chloroform, heating reflux reaction 10h, TLC monitor raw material fully reacting, and filtering is anti- Liquid is answered, obtains N- (2- (4- piperidone base) phenyl) pivaloyl amine after filtrate concentration;Or in reaction flask, N- (2- (hydroxyl Base (4- pyridyl group) methyl) phenyl) pivaloyl amine and CrO3It is added in chloroform, reacts at room temperature 5h, it is anti-that TLC monitors raw material Should reaction solution be extracted with ethyl acetate after filtering, obtain N- (2- (4- piperidone base) phenyl) front three after organic phase is evaporated off completely Yl acetamide.
It further limits, the detailed process of step D are as follows: in reaction flask, N- (2- (4- piperidone base) phenyl) front three Yl acetamide is added in the mixed solution of ethyl alcohol and hydrochloric acid, is stirred to react at room temperature, is heated to after stirring 2h Reflux, the reaction was continued 6h, TLC monitoring raw material fully reacting;Ethyl alcohol is evaporated off in vacuum concentration, then is adjusted instead with saturated sodium carbonate solution Answering liquid pH is 7~8, then reaction solution is extracted with dichloromethane three times, is concentrated to get 2- (4- piperidone base) benzene after merging organic phase The crude product of amine, then sterling is obtained through column chromatography for separation;Obtained 2- (4- piperidone base) aniline adding into dichloromethane, Compound Boc glycyl chlorine and DCC are added, reacts 10h at room temperature, TLC monitors raw material fully reacting, and filtering is anti- Liquid is answered to remove dicyclohexylurea, reaction solution is washed with 10% HCl solution and saturated sodium carbonate solution respectively again, after separating organic phase It is concentrated to get N- (2- (4- piperidone base) phenyl) Boc amino acetamide crude product, then obtains sterling through column chromatography for separation.
It further limits, the detailed process of step E are as follows: in reaction flask, N- (2- (4- piperidone base) phenyl) Boc ammonia Yl acetamide is added in Isosorbide-5-Nitrae-dioxane containing 4M HCl, is stirred to react 2h at room temperature, it is anti-that TLC monitors raw material Should completely, filtering reacting liquid, filter cake is N- (2- (4- piperidone base) phenyl) glycyl amine hydrochlorate;Or in reaction flask, N- (2- (4- piperidone base) phenyl) Boc amino acetamide is added in the THF containing 4M HCl, is stirred under heated reflux condition Reaction 2h is mixed, TLC monitors raw material fully reacting, filtering reacting liquid, and filter cake is N- (2- (4- piperidone base) phenyl) glycyl Amine hydrochlorate.
It further limits, the detailed process of step F are as follows: in reaction flask, N- (2- (4- piperidone base) phenyl) amino Acetamide hydrochloride and sodium methoxide are added in methanol, 2h are stirred to react at 50 DEG C, LCMS monitors raw material fully reacting, true Reaction dissolvent is evaporated off under empty condition, adds a certain amount of water and methylene chloride, separates organic phase, 5- (4- pyrrole is obtained after concentration Piperidinyl) tall and erect -2 (3H) -one of -1H- benzo [e] [1,4] phenodiazine.
Further limit, the detailed process of step G are as follows: in reaction flask, 5- (4- pyridyl group) -1H- benzo [e] [1, 4] tall and erect -2 (3H) -one of phenodiazine and TMSN3It is added in acetone, adds a certain amount of potassium carbonate, room temperature is anti-under nitrogen protection 2h, TLC is answered to monitor raw material fully reacting, reaction solution is extracted with dichloromethane after certain water is added, it is concentrated after merging organic phase, It is obtained again through column chromatography for separationOr in reaction flask, 5- (4- pyridyl group) -1H- benzo [e] [Isosorbide-5-Nitrae] two Nitrogen -2 (3H) -one of Zhuo and NaN3It is added in DMF, adds a certain amount of CuI and potassium carbonate, be heated under air conditions 120 DEG C, TLC monitors raw material fully reacting after reacting 6h, and reaction solution is extracted with dichloromethane after certain water is added, and merges organic phase After be concentrated, then obtained through column chromatography for separation
Specific embodiment
Above content of the invention is described in further details by the following examples, but this should not be interpreted as to this The range for inventing above-mentioned theme is only limitted to embodiment below, and all technologies realized based on above content of the present invention belong to this hair Bright range.
Embodiment 1
In reaction flask, aniline (10g, 0.107mol) is added in pyridine 50mL, at room temperature, spy is slowly added dropwise Valeric chloride (14.24g, 0.118mol) continues to react 3h at room temperature after dripping, and TLC monitors raw material fully reacting, to Be added a certain amount of 6N HCl solution in reaction solution, strong stirring for a period of time after washed reaction liquid, finally under vacuum conditions It is concentrated to get N- phenyl trimethicone acetamide (18g, yield:95.23%) .MS (ESI) m/z:177.1 (M+H+). HNMR: (CDCl3) δ 7.38 (brs, 1H, NH), 7.55 (d, J=8Hz, 2H, Ar-H), 7.36 (t, J=8Hz, 2H, Ar-H), 7.20 (t, J=4Hz, 1H, Ar-H), 1.40 (s, 9H)
Embodiment 2
In reaction flask, methylene chloride is added in aniline (10g, 0.107mol) and potassium carbonate (27.6g, 0.20mol) It is stirred in 50ml, at room temperature, pivaloyl chloride (14.24g, 0.118mol) is slowly added dropwise, continued after dripping in room temperature Under the conditions of react 3h, TLC monitors raw material fully reacting, and a certain amount of 6N HCl solution, strong stirring one are added into reaction solution Section the time after washed reaction liquid, be finally concentrated to get under vacuum conditions N- phenyl trimethicone acetamide (15.7g, yield: 82.78%) .MS (ESI) m/z:177.1 (M+H+).
Embodiment 3
In reaction flask, N- phenyl trimethicone acetamide (10g, 0.056mol) is added to the THF through Non-aqueous processing In 100mL, nitrogen protection reaction system is placed under the conditions of 0 DEG C, n-butyllithium solution is slowly added dropwise, maintain the temperature at 5 DEG C with Under, about 30min is added dropwise complete;After stirring 2h, the THF solution 50mL dissolved with 4- pyridine carboxaldehyde 12g, it is slowly dropped to reaction solution In, so that reaction temperature is no more than 5 DEG C, drips rear reaction solution in peony;It is complete that the reaction was continued 3h, TLC monitor raw material unreacted Entirely, make reaction that a certain amount of ice water quenching reaction be added after the reaction was continued 8h under the conditions of 60 DEG C of temperature, then use ethyl acetate Reaction solution is extracted, obtains the crude product of N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine after organic phase is evaporated off, Sterling (3.4g, yield:21.38%) .MS (ESI) m/z:285.4 (M+H is obtained through column chromatography for separation again+).HNMR: (CDCl3) δ 8.94 (brs, 1H, NH), 8.27 (d, J=6Hz, 2H, Ar-H), 8.09 (d, J=8Hz, 1H, Ar-H), 7.24- 7.34 (m, 1H, Ar-H), 8.29 (d, J=6Hz, 2H, Ar-H), 7.22 (d, J=5.2Hz, 2H, Ar-H), 8.38 (d, J= 6Hz, 2H, Ar-H), 7.01 (d, J=3.6Hz, 2H, Ar-H), 5.65 (s, 1H), 1.04 (s, 9H)
Embodiment 4
In reaction flask, N- phenyl trimethicone acetamide (10g, 0.056mol) is added to the THF through Non-aqueous processing In 100mL, nitrogen protection reaction system is placed under the conditions of 0 DEG C, n-butyllithium solution is slowly added dropwise, maintain the temperature at 5 DEG C with Under, about 30min is added dropwise complete;After stirring 2h, the THF solution 50mL dissolved with 4- pyridine carboxaldehyde 12g, it is slowly dropped to reaction solution In, so that reaction temperature is no more than 5 DEG C, drips rear reaction solution in peony;It is complete that the reaction was continued 3h, TLC monitor raw material unreacted Entirely, make reaction that a certain amount of ice water quenching reaction be added after the reaction was continued 8h under the conditions of -20 DEG C of temperature, then use ethyl acetate Reaction solution is extracted, obtains the crude product of N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine after organic phase is evaporated off, Sterling (12.7g, yield:79.21%) .MS (ESI) m/z:285.4 (M+H is obtained through column chromatography for separation again+)。
Embodiment 5
In reaction flask, N- phenyl trimethicone acetamide (10g, 0.056mol) is added to the THF through Non-aqueous processing In 100mL, nitrogen protection reaction system is placed under the conditions of 0 DEG C, n-butyllithium solution is slowly added dropwise, maintain the temperature at 5 DEG C with Under, about 30min is added dropwise complete;After stirring 2h, the THF solution 50mL dissolved with 4- pyridine carboxaldehyde 12g, it is slowly dropped to reaction solution In, so that reaction temperature is no more than 5 DEG C, drips rear reaction solution in peony;It is complete that the reaction was continued 3h, TLC monitor raw material unreacted Entirely, make reaction that a certain amount of ice water quenching reaction be added after the reaction was continued 8h under the conditions of 10 DEG C of temperature, then use ethyl acetate Reaction solution is extracted, obtains the crude product of N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine after organic phase is evaporated off, Sterling (13.3g, yield:83.23%) .MS (ESI) m/z:285.4 (M+H is obtained through column chromatography for separation again+)。
Embodiment 6
In reaction flask, N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine (6g, 0.021mol) And MnO2(9.2g, 0.021mol) is added in chloroform 50mL, and heating reflux reaction 10h, TLC monitor raw material fully reacting, mistake Filter reaction solution, filtrate concentration after obtain N- (2- (4- piperidone base) phenyl) pivaloyl amine (4.8g, yield: 82.11%) .MS (ESI) m/z:283.4 (M+H+).MS(ESI)m/z:283.4(M+H+).HNMR:(CDCl3)δ11.35 (brs, 1H, NH), 8.77-8.79 (m, 3H, Ar-H), 7.60 (t, J=7.6Hz, 1H, Ar-H), 7.50-7.49 (m, 3H, Ar- ), H 7.03 (t, J=7.2Hz, 1H, Ar-H), 1.06 (s, 9H)
Embodiment 7
In reaction flask, N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine (6g, 0.021mol) And CrO3(2.1g, 0.021mol) is added in chloroform 50mL, reacts at room temperature 5h, TLC monitors raw material fully reacting, after filtering Reaction solution is extracted with ethyl acetate, be evaporated off after organic phase obtain N- (2- (4- piperidone base) phenyl) pivaloyl amine (5.4g, Yield:92.30%) .MS (ESI) m/z:283.4 (M+H+).
Embodiment 8
In reaction flask, N- (2- (4- piperidone base) phenyl) pivaloyl amine (4.2g, 0.0154mol) is added to It in the mixed solution of ethyl alcohol 35mL and hydrochloric acid 14mL, is stirred to react at room temperature, is heated to flowing back after stirring 2h, The reaction was continued 6h, TLC monitoring raw material fully reacting;Ethyl alcohol is evaporated off in vacuum concentration, then adjusts reaction solution with saturated sodium carbonate solution PH is 7~8, then reaction solution is extracted with dichloromethane three times, is concentrated to get 2- (4- piperidone base) aniline after merging organic phase Crude product, then sterling (2.5g, yield:83%) .MS (ESI) m/z:199.2 (M+H is obtained through column chromatography for separation+).HNMR: (CDCl3) δ 8.75-8.76 (m, 2H, Ar-H), 7.44 (d, 2H, Ar-H), 7.43 (d, 2H, Ar-H), 6.75 (d, 1H, J= 8Hz,Ar-H),6.57-6.61(m,1H,Ar-H),6.32(brs,2H,NH).
Embodiment 9
In reaction flask, 2- (4- piperidone base) aniline (2g, 0.01mol) is added in methylene chloride 50mL, then plus Enter Boc glycyl chlorine (3.8g, 0.02mol) and DCC (4.12g, 0.02mol), reacts 7h, TLC prison at room temperature Control raw material fully reacting, filtering reacting liquid remove dicyclohexylurea, reaction solution again respectively with 10% HCl solution and saturated sodium carbonate Solution washing, is concentrated to get N- (2- (4- piperidone base) phenyl) Boc amino acetamide crude product after separating organic phase, then through column layer Analyse isolated sterling (2.2g.yield:60%) .MS (ESI) m/z:356.4 (M+H+).HNMR:(CDCl3)δ 11.46 (brs, 1H, NH), 8.79 (t, 3H, J=4Hz, Ar-H), 8.72 (d, 1H, J=4Hz, Ar-H), 7.45-7.61 (m, 4H, Ar- ), H 5.36 (brs, 1H, NH), 4.00 (d, J=8Hz, 2H), 1.45 (s, 9H)
Embodiment 10
In reaction flask, N- (2- (4- piperidone base) phenyl) Boc amino acetamide (2g, 0.0056mol) is added to In Isosorbide-5-Nitrae-dioxane containing 4M HCl, it is stirred to react 2h at room temperature, TLC monitors raw material fully reacting, and filtering is anti- Liquid is answered, filter cake is N- (2- (4- piperidone base) phenyl) glycyl amine hydrochlorate (1.2g, yield:75%) .MS (ESI) m/ z: 256.4(M+H+).HNMR:(CDCl3) δ 8.66 (t, 3H, J=4Hz, Ar-H), 8.43 (d, 1H, J=4Hz, Ar-H), 7.38-7.61 (m, 4H, Ar-H), 7.23 (brs, 1H, NH), 3.85 (d, J=8Hz, 2H), 1.53 (s, 2H)
Embodiment 11
In reaction flask, N- (2- (4- piperidone base) phenyl) Boc amino acetamide (2g, 0.0056mol) is added to In THF containing 4M HCl, 2h is stirred to react under heated reflux condition, TLC monitors raw material fully reacting, filtering reacting liquid, filter Cake is N- (2- (4- piperidone base) phenyl) glycyl amine hydrochlorate (1.5g, yield:93.56%) .MS (ESI) m/z: 256.4 (M+H+).
Embodiment 12
In reaction flask, N- (2- (4- piperidone base) phenyl) glycyl amine hydrochlorate (700mg, 2.41mmol) and Sodium methoxide (155.8mg, 2.88mmol) is added in methanol 20mL, and 2h, LC-MS monitoring reaction are stirred to react under the conditions of 50 DEG C Completely, reaction dissolvent is evaporated off under vacuum conditions, adds a certain amount of water and methylene chloride, separates organic phase, after concentration To -2 (3H) -one (450mg, yield:78.81%) .MS (ESI) m/ of 5- (4- pyridyl group) -1H- benzo [e] [1,4] phenodiazine Zhuo z: 238.3(M+H+).HNMR:(CDCl3) δ 9.37 (brs, 1H, NH), 8.68 (s, 2H, Ar-H), 7.54 (d, 1H, J=8Hz, Ar-H),7.45(s,2H,Ar-H),7.20-7.27(m,3H,Ar-H),4.38(s,2H).
Embodiment 13
In reaction flask, tall and erect -2 (3H) -one of 5- (4- pyridyl group) -1H- benzo [e] [Isosorbide-5-Nitrae] phenodiazine (300mg, 1.26mmol) and TMSN3(130mg, 1.52mmol) is added in acetone 20mL, add potassium carbonate (170mg, 1.26mmol), 2h is reacted at room temperature under nitrogen protection, and TLC monitors raw material fully reacting, reaction solution is poured into water 50mL, uses Methylene chloride 20mL extracts reaction solution three times, merges organic phase, solvent is evaporated off and obtains(299mg, Yield:90.55%) MS (ESI) m/z:262.1 (M+H+).HNMR:(DMSO-d6)δ11.79(s,1H,NH),8.68(s, 2H,Ar-H), 7.88(m,2H,Ar-H),7.58(m,1H,Ar-H),6.68-7.22(m,3H,Ar-H),4.22(s,1H).
Embodiment 14
In reaction flask, tall and erect -2 (3H) -one of 5- (4- pyridyl group) -1H- benzo [e] [Isosorbide-5-Nitrae] phenodiazine (300mg, 1.26mmol) and NaN3(99mg, 1.52mmol) is added in DMF20mL, adds CuI (71.5mg, 0.50mmol) and carbon Sour potassium (68.97mg, 0.50mmol) is heated to 120 DEG C under air conditions, and TLC monitors raw material fully reacting after reacting 6h, Reaction solution is extracted with dichloromethane after certain water is added, and is concentrated after merging organic phase, then obtain through column chromatography for separation(258mg, yield:77.8%) .MS (ESI) m/z:262.1 (M+H+).
Embodiment 15
Anti-tumor activity test
Growth period breast cancer cell MCF-7 and liver cancer HepG2 is collected, the anticancer activity of compound is measured with MTS method, By cell with (every milliliter 4 × 10 of debita spissitudo4A cell) it is added in 96 porocyte culture plates and (must be trained containing 10% tire calf serum Nutrient solution is made into individual cells suspension), after culture 24 hours, in 37 DEG C, the CO that volumetric concentration is 5%2Under the conditions of with various concentration Compound effects 72 hours, then by the mixing of MTS (final mass concentration 2mg/mL) and DMS (30 μM of final molar concentration) Object is directly added into celliferous culture medium, continues to set incubator incubation 4h.After acting on 4h, liquid is discarded supernatant, every hole is added 150 μ LDMSO, oscillation, cell survival rate pass through its suction to the metabolin of MTS effect under enzyme linked immunological monitor 490nm wavelength Yield measurement.
Preliminary biological activity test shows that the compound has inhibition to make breast cancer cell MCF-7 and liver cancer HepG2 With, but it is better than the inhibiting effect to breast cancer cell MCF-7 to the inhibiting effect of hepatocellular carcinoma H22.
Embodiment above describes basic principles and main features of the invention and advantage, the technical staff of the industry should Understand, the present invention is not limited to the above embodiments, and the above embodiments and description only describe originals of the invention Reason, under the range for not departing from the principle of the invention, various changes and improvements may be made to the invention, these changes and improvements are each fallen within In the scope of protection of the invention.

Claims (10)

1. a kind of triazole with anti-tumor activity and phenodiazine Zhuo compound, it is characterised in that its molecular structural formula are as follows:
2. the preparation method of a kind of triazole with anti-tumor activity described in claim 1 and phenodiazine Zhuo compound, special Sign is specific steps are as follows:
A, acylation reaction generation N- phenyl trimethicone acetamide occurs in pyridine or methylene chloride for aniline and pivaloyl chloride;
B, N- phenyl trimethicone acetamide activates under that action of n-butyl lithium occurs addition reaction with 4- pyridine carboxaldehyde after ortho-hydrogens Obtain N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine;
C, N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine is aoxidized by manganese dioxide or chromium trioxide, knot Secondary carbon and the hydroxyl connected generate carbonyl after sloughing a molecule hydrogen on structure, obtain N- (2- (4- pyriconyl) phenyl) front three Yl acetamide;
D, N- (2- (4- pyriconyl) phenyl) pivaloyl amine sloughs tertiary bytyry in acid condition and obtains 2- (4- pyridine Ketone group) aniline;2- (4- pyriconyl) aniline occurs substitution reaction with Boc glycyl chlorine under DCC effect and generates N- (2- (4- pyriconyl) phenyl) Boc amino acetamide;
E, N- (2- (4- pyriconyl) phenyl) Boc amino acetamide is reacted in Isosorbide-5-Nitrae-dioxane or THF with HCl, is sloughed N- (2- (4- pyriconyl) phenyl) glycyl amine hydrochlorate is obtained at salt while Boc group;
F, N- (2- (4- pyriconyl) phenyl) glycyl amine hydrochlorate occurs ketoamine and is condensed to yield 5- under sodium methoxide effect (4- pyridyl group) -1H- benzo [e] [1,4] phenodiazine -2 (3H) -one of Zhuo;
G, tall and erect -2 (3H) -one of 5- (4- pyridyl group) -1H- benzo [e] [1,4] phenodiazine and TMSN3Or NaN3Click reaction is occurring It obtains
3. the preparation method of a kind of triazole with anti-tumor activity according to claim 2 and phenodiazine Zhuo compound, It is characterized in that the detailed process of step A are as follows: in reaction flask, aniline is added in pyridine, at room temperature, is slowly added dropwise Pivaloyl chloride continues to react at room temperature after dripping, and TLC monitors raw material fully reacting, is added into reaction solution certain The HCl solution of amount, strong stirring for a period of time after washed reaction liquid, be finally concentrated to get N- phenyl trimethicone under vacuum conditions Acetamide;Or in reaction flask, aniline and potassium carbonate are added in methylene chloride and stirred, at room temperature, spy is slowly added dropwise Valeric chloride continues to react at room temperature after dripping, and TLC monitors raw material fully reacting, is added into reaction solution a certain amount of HCl solution, strong stirring for a period of time after washed reaction liquid, be finally concentrated to get N- phenyl trimethicone second under vacuum conditions Amide.
4. the preparation method of a kind of triazole with anti-tumor activity according to claim 2 and phenodiazine Zhuo compound, It is characterized in that the detailed process of step B are as follows: in reaction flask, N- phenyl trimethicone acetamide is added to through Non-aqueous processing In THF, nitrogen protection reaction system is placed under the conditions of 0 DEG C, n-butyllithium solution is slowly added dropwise, maintain the temperature at 5 DEG C hereinafter, 2h is stirred after dripping, the THF solution dissolved with 4- pyridine carboxaldehyde is slowly dropped in reaction solution, and reaction temperature is made to be no more than 5 DEG C, rear reaction solution is dripped in peony;It is complete that the reaction was continued 3h, TLC monitor raw material unreacted, makes reaction in temperature -20 DEG C~40 DEG C under the conditions of a certain amount of ice water quenching reaction is added after the reaction was continued 8h, then reaction solution is extracted with ethyl acetate, steams Except the crude product for obtaining N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) pivaloyl amine after organic phase, then through column chromatography for separation Obtain sterling.
5. the preparation method of a kind of triazole with anti-tumor activity according to claim 2 and phenodiazine Zhuo compound, It is characterized in that the detailed process of step C are as follows: in reaction flask, N- (2- (hydroxyl (4- pyridyl group) methyl) phenyl) trimethyl Acetamide and MnO2It is added in chloroform, heating reflux reaction 10h, TLC monitor raw material fully reacting, filtering reacting liquid, filtrate N- (2- (4- pyriconyl) phenyl) pivaloyl amine is obtained after concentration;Or in reaction flask, N- (2- (hydroxyl (4- pyridine Base) methyl) phenyl) pivaloyl amine and CrO3It is added in chloroform, reacts at room temperature 5h, TLC monitors raw material fully reacting, mistake Reaction solution is extracted with ethyl acetate after filter, obtains N- (2- (4- pyriconyl) phenyl) pivaloyl amine after organic phase is evaporated off.
6. the preparation method of a kind of triazole with anti-tumor activity according to claim 2 and phenodiazine Zhuo compound, It is characterized in that the detailed process of step D are as follows: in reaction flask, N- (2- (4- pyriconyl) phenyl) pivaloyl amine is added Enter into the mixed solution of ethyl alcohol and hydrochloric acid, be stirred to react at room temperature, be heated to flowing back after stirring 2h, continues anti- 5h, TLC is answered to monitor raw material fully reacting;Ethyl alcohol is evaporated off in vacuum concentration, then adjusts reaction solution pH > 7 with saturated sodium carbonate solution, then Reaction solution is extracted with dichloromethane three times, the crude product of 2- (4- pyriconyl) aniline is concentrated to get after merging organic phase, then through column Chromatography obtains sterling;Obtained 2- (4- pyriconyl) aniline adding into dichloromethane, compound Boc is added Glycyl chlorine and DCC react 10h at room temperature, and TLC monitors raw material fully reacting, and filtering reacting liquid removes two hexamethylenes Urea, reaction solution are washed with 10% HCl solution and saturated sodium carbonate solution respectively again, are concentrated to get N- (2- after separating organic phase (4- pyriconyl) phenyl) Boc amino acetamide crude product, then sterling is obtained through column chromatography for separation.
7. the preparation method of a kind of triazole with anti-tumor activity according to claim 2 and phenodiazine Zhuo compound, It is characterized in that the detailed process of step E are as follows: in reaction flask, N- (2- (4- pyriconyl) phenyl) Boc amino acetamide It being added in Isosorbide-5-Nitrae-dioxane containing 4M HCl, is stirred to react 2h at room temperature, TLC monitors raw material fully reacting, Filtering reacting liquid, filter cake are N- (2- (4- pyriconyl) phenyl) glycyl amine hydrochlorate;Or in reaction flask, N- (2- (4- pyriconyl) phenyl) Boc amino acetamide is added in the THF containing 4M HCl, is stirred to react under heated reflux condition 2h, TLC monitor raw material fully reacting, filtering reacting liquid, and filter cake is N- (2- (4- pyriconyl) phenyl) amino acetamide hydrochloric acid Salt.
8. the preparation method of a kind of triazole with anti-tumor activity according to claim 2 and phenodiazine Zhuo compound, It is characterized in that the detailed process of step F are as follows: in reaction flask, N- (2- (4- pyriconyl) phenyl) amino acetamide hydrochloric acid Salt and sodium methoxide are added in methanol, and 2h is stirred to react at 50 DEG C, and LCMS monitors raw material fully reacting, steams under vacuum conditions Except reaction dissolvent, a certain amount of water and methylene chloride are added, separates organic phase, 5- (4- pyridyl group) -1H- benzene is obtained after concentration And tall and erect -2 (3H) -one of [e] [1,4] phenodiazine.
9. the preparation method of a kind of triazole with anti-tumor activity according to claim 2 and phenodiazine Zhuo compound, It is characterized in that the detailed process of step G are as follows: in reaction flask, 5- (4- pyridyl group) -1H- benzo [e] [Isosorbide-5-Nitrae] phenodiazine Zhuo -2 (3H) -one and TMSN3It is added in acetone, adds a certain amount of potassium carbonate, react at room temperature 2h, TLC prison under nitrogen protection Raw material fully reacting is controlled, reaction solution is extracted with dichloromethane after certain water is added, and is concentrated after merging organic phase, then through column chromatography point From obtainingOr in reaction flask, 5- (4- pyridyl group) -1H- benzo [e] [Isosorbide-5-Nitrae] phenodiazine Zhuo -2 (3H) - Ketone and NaN3It is added in DMF, adds a certain amount of CuI and potassium carbonate, 120 DEG C are heated under air conditions, react 6h TLC monitors raw material fully reacting afterwards, and reaction solution is extracted with dichloromethane after certain water is added, and is concentrated after merging organic phase, then pass through Column chromatography for separation obtains
10. simultaneously phenodiazine Zhuo compound is preparing anti-tumor drug to triazole with anti-tumor activity as described in claim 1 In application.
CN201711220507.8A 2017-11-29 2017-11-29 Triazole with anti-tumor activity and phenodiazine Zhuo compound and preparation method thereof Active CN107759607B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711220507.8A CN107759607B (en) 2017-11-29 2017-11-29 Triazole with anti-tumor activity and phenodiazine Zhuo compound and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711220507.8A CN107759607B (en) 2017-11-29 2017-11-29 Triazole with anti-tumor activity and phenodiazine Zhuo compound and preparation method thereof

Publications (2)

Publication Number Publication Date
CN107759607A CN107759607A (en) 2018-03-06
CN107759607B true CN107759607B (en) 2019-08-23

Family

ID=61276144

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711220507.8A Active CN107759607B (en) 2017-11-29 2017-11-29 Triazole with anti-tumor activity and phenodiazine Zhuo compound and preparation method thereof

Country Status (1)

Country Link
CN (1) CN107759607B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527334B (en) * 2020-04-13 2022-04-29 济南爱思医药科技有限公司 Triazole derivative capable of influencing calcium ion channel of tumor cell and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762569A (en) * 2009-11-05 2012-10-31 葛兰素史克有限责任公司 Benzodiazepine bromodomain inhibitor
CN103827120A (en) * 2011-09-01 2014-05-28 拜耳知识产权有限责任公司 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
CN105189514A (en) * 2013-02-22 2015-12-23 拜耳医药股份有限公司 Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases
CN105899212A (en) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 Method of treating diffuse large B-cell lymphoma (DLBCL) using a beta-bromodomain inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09157261A (en) * 1995-12-07 1997-06-17 Yoshitomi Pharmaceut Ind Ltd Phenylazole compound and benzotriazolodiazepine compound
US9085582B2 (en) * 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762569A (en) * 2009-11-05 2012-10-31 葛兰素史克有限责任公司 Benzodiazepine bromodomain inhibitor
CN103827120A (en) * 2011-09-01 2014-05-28 拜耳知识产权有限责任公司 6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
CN105189514A (en) * 2013-02-22 2015-12-23 拜耳医药股份有限公司 Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases
CN105899212A (en) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 Method of treating diffuse large B-cell lymphoma (DLBCL) using a beta-bromodomain inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors;Steven G. Smith et al.;《Chemistry & Biology》;20140522;第21卷;第573-583页

Also Published As

Publication number Publication date
CN107759607A (en) 2018-03-06

Similar Documents

Publication Publication Date Title
CA2359948C (en) Triazole compounds with dopamine-d3-receptor affinity
CA2874110C (en) Processes to produce certain 2-(pyridine-3-yl)thiazoles
CN102066353B (en) Disubstituted phthalazine Hedgehog pathway antagonists
KR102562286B1 (en) Synthesis of copanlisib and its dihydrochloride salt
AU2010228902A1 (en) Process for the preparation of alogliptin
WO2005113518A1 (en) Process for preparing irbesartan
KR101701362B1 (en) Synthesis of a neurostimulative piperazine
KR20090081028A (en) Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CN104744334A (en) Preparation method for vildagliptin
CN107759607B (en) Triazole with anti-tumor activity and phenodiazine Zhuo compound and preparation method thereof
CN115626913A (en) Method for preparing key intermediate of remimazolam
CN107531677A (en) Method for preparing Topiroxostat and its intermediate
CN110655517A (en) Preparation method of doriravir open-loop impurities and impurities thereof
CN107903244B (en) 2- amido with anti-tumor activity replaces Benzodiazepine compound and preparation method thereof
CN105153169B (en) A kind of synthetic method of epinastine hydrochloride
EP1611139A1 (en) Methods of preparing olanzapine
CN107759606B (en) Azepine cycloolefin with anti-tumor activity and phenodiazine Zhuo drug molecule and preparation method thereof
CN105636952A (en) Secondary alcohol quinolinyl modulators of roryt
CN111848546A (en) 2- (aminomethyl) thiazole-5-nitrile and synthesis method thereof
WO1988002751A1 (en) Pyridine derivatives
CN107936032A (en) A kind of new diazepine tricyclic compounds and its preparation method and application
EP3356372B1 (en) Novel process for preparing thienopyrimidine compound and intermediates used therein
CA2540021A1 (en) Hcv inhibitors and methods of using them
CA2956268A1 (en) Pyrazole derivative manufacturing method
JP2020536898A (en) Process for preparing spiro derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190729

Address after: No. 298 Huachuang Road, Jinshan District, Shanghai, 201500

Applicant after: Shanghai Wanxiang Pharmaceutical Co., Ltd.

Address before: 453000 College Road, Muye District, Xinxiang City, Henan Province

Applicant before: Henan Longhu Biological Technology Co., Ltd.

GR01 Patent grant
GR01 Patent grant